The state of Texas currently has 34 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
NCT05329194
Recruiting
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
04/10/2024
Locations: Research Site, Dallas, Texas +3 locations
Conditions: Asthma
Register for Updates
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
NCT06033833
Recruiting
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enr... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/10/2024
Locations: TTS Research Site Number : 8400011, Boerne, Texas
Conditions: Asthma
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/05/2024
Locations: Research Site, Austin, Texas +15 locations
Conditions: Asthma
Register for Updates
Dupilumab Effects Against Aeroallergen Challenge
NCT05720325
Recruiting
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/05/2024
Locations: Biogenics Research Chamber, San Antonio, Texas +1 locations
Conditions: Asthma, Allergic
Register for Updates
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
NCT05755906
Recruiting
This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
04/04/2024
Locations: Research Site, Amarillo, Texas +12 locations
Conditions: Asthma
Register for Updates
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
NCT05202262
Recruiting
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
04/03/2024
Locations: Research Site, Amarillo, Texas +14 locations
Conditions: Asthma
Register for Updates
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
NCT05660850
Recruiting
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Pharmaceutical Research & Consulting, Inc., Dallas, Texas
Conditions: Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
All
Ages:
Between 0 years and 20 years
Trial Updated:
03/29/2024
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +3 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
03/29/2024
Locations: Research Site, Amarillo, Texas +24 locations
Conditions: Asthma
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
All
Ages:
Between 6 years and 18 years
Trial Updated:
03/25/2024
Locations: Research Site, Dallas, Texas +2 locations
Conditions: Asthma
Register for Updates
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
NCT03373045
Recruiting
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based survey... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Aransas Pass, Texas +12 locations
Conditions: Asthma
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: REX Clinical Trials Site Number : 8400135, Beaumont, Texas +9 locations
Conditions: Asthma
Register for Updates